Anteris Technologies Stock price
Compare with Peer Group
Is Anteris Technologies a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,133 stocks worldwide.
Key metrics
Anteris Technologies Stock Analysis
Analyst Opinions
8 Analysts have issued a Anteris Technologies forecast:
Analyst Opinions
8 Analysts have issued a Anteris Technologies forecast:
Don't miss a Thing! We will send you all news about Anteris Technologies directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Anteris Technologies Stock News
Company Profile
Anteris Technologies Global Corp. is a structural heart company, which engages in the development and commercialization of medical devices for heart diseases. The company is headquartered in Eagan, Minnesota and currently employs 174 full-time employees. The company went IPO on 2024-12-13. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The firm's ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.
| Head office | United States |
| CEO | Mr. Paterson |
| Employees | 174 |
| Website | anteristech.com |


